股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | | 20,000,000,000 | HKD | | 0.2 HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： HKD ...

Group 1 - The company Guodi Technology (002694) announced that its net assets are expected to be negative by the end of 2025, which may lead to a delisting risk warning for its stock [1][3] - On February 2, the company's stock price hit the daily limit down, closing at 3.33 yuan per share [1] - Guodi Technology's 2025 performance forecast indicates a projected net loss attributable to shareholders of 300 million to 577 million yuan, with a non-recurring net profit loss of 63.21 million to 123 million yuan [3] Group 2 - The anticipated negative net assets are primarily due to provisions for pending litigation losses, estimated between 280 million to 410 million yuan [3] - The company is attempting to improve its sales strategies, product structure, and expand its dealer network to enhance gross profit margins, while also focusing on internal management and cost control [3] - Guodi Technology has faced significant litigation costs, including a case with Zhejiang Jinggong Steel Structure Group, which has resulted in a cumulative provision loss exceeding 287 million yuan [5] Group 3 - The company has diversified into the cultural tourism sector, investing approximately 1 billion yuan in the Alxa Desert Dream Car Aviation Park project, but this has not yielded the expected returns [4] - Guodi Technology is currently involved in multiple legal disputes, including a second-instance case with Zhejiang Jinggong and a construction contract dispute with Ningxia Construction Group, which has led to additional provisions totaling 109.45 million yuan [5][6] - The company has engaged a professional legal team to address these ongoing legal challenges [6]

奇瑞集团公布了2026年首月成绩单，总销量突破20万辆，达到200269辆。其中，新能源汽车销量达 到了52131辆，出口量同比增长了48.1%，达到了119605辆。 ...

Core Viewpoint - *ST Shuangcheng (002693.SZ) is expected to turn a profit in 2025, with net profit attributable to shareholders projected between 16 million to 23 million yuan, marking a significant turnaround from losses in the previous year [1] Financial Performance - The company anticipates a total profit growth of 107.53% to 111.30% year-on-year, with net profit attributable to shareholders expected to increase by 120.43% to 129.37% [1] - Revenue is projected to be between 250 million to 290 million yuan [1] Factors Influencing Profit Changes - The company is focusing on international development to counteract domestic drug price declines, leading to steady growth in export sales and advancements in overseas R&D projects [1] - The approval of the U.S. registration application for injectable paclitaxel (albumin-bound) is expected to drive significant revenue growth following its rapid sales post-approval [1] - The absence of fair value loss from Zhongrong Trust financial products, which impacted the previous year's results, and a reduction in asset impairment losses have also contributed to the turnaround [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has been recognized as a high-tech enterprise in Ningbo for the first batch of 2025, which will provide tax benefits for the next three years [1] Group 1: Company Recognition - Ningbo Shuangcheng Pharmaceutical Co., Ltd., a subsidiary of Hainan Shuangcheng Pharmaceutical Co., Ltd., has been certified as a high-tech enterprise by the Ningbo Municipal High-tech Enterprise Recognition Management Work Leading Group [1] - The high-tech enterprise certificate number is GR202533101446, issued on December 8, 2025, and is valid for three years [1] Group 2: Tax Benefits - Following the recognition, Ningbo Shuangcheng will enjoy a preferential corporate income tax rate of 15% for three consecutive years, as per the relevant provisions of the Corporate Income Tax Law of the People's Republic of China [1] Group 3: Impact on Financial Performance - The recognition will not have an impact on the company's current operating performance [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國資源交通集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00269 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.2 | HKD | | 4,000,000,000 | 本月底法定/註冊股本總額： H ...

Group 1 - The core point of the article is that *ST Shuangcheng (002693.SZ) has received FDA approval for its injectable bortezomib ANDA product [1] Group 2 - The company announced the FDA approval on its investor interaction platform [1]

Group 1 - The core viewpoint of the article is that *ST Shuangcheng (002693.SZ) has confirmed that several of its products are included in the medical insurance catalog [1] - The products that are included in the medical insurance catalog are: Thymosin injection, Somatostatin injection, Famotidine injection, Clindamycin hydrochloride injection, Chuanxiong phosphate injection, and Octreotide acetate injection [1] - The company has not submitted an application for its product, Paclitaxel injection (albumin-bound), in the domestic market [1]

Core Viewpoint - Hainan Shuangcheng Pharmaceutical Co., Ltd. has received FDA approval for its injectable Bortezomib ANDA, marking a significant milestone in its international expansion and product portfolio enhancement [1] Group 1: Company Performance - As of December 18, 2025, *ST Shuangcheng (002693) closed at 6.58 yuan, down 0.3% from the previous trading day, with a total market capitalization of 2.729 billion yuan [1] - The stock opened at 6.59 yuan, reached a high of 6.79 yuan, and a low of 6.55 yuan, with a trading volume of 32.0879 million yuan and a turnover rate of 1.17% [1] Group 2: Regulatory Approvals - The injectable Bortezomib ANDA has been recognized by the FDA as being bioequivalent and therapeutically equivalent to the reference drug [1] - The product has also received approval from the National Medical Products Administration of China and has passed the consistency evaluation, along with obtaining listing permission from Australia's TGA [1] Group 3: Strategic Implications - The FDA approval signifies that the company's product meets international standards, which is expected to enhance its international influence and operational performance [1] - This development will enrich the company's international sales product line and advance its globalization strategy [1] - The announcement also notes that overseas sales may be affected by regulations, policies, market conditions, and exchange rate fluctuations [1]

Core Viewpoint - The company *ST Shuangcheng has received approval from the U.S. FDA for its abbreviated new drug application (ANDA) for injectable bortezomib, indicating that the product is bioequivalent and therapeutically equivalent to the reference drug [1] Group 1: FDA Approval - The U.S. FDA has completed a comprehensive technical review of the ANDA submitted by the company [1] - The approval confirms that the company's product is equivalent in terms of biological and therapeutic effects to the original drug [1] Group 2: Approved Indications - The approved indications for the injectable bortezomib include: 1. Treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1] 2. Part of a combination therapy for previously untreated multiple myeloma patients under 65 years old, used for high-dose chemotherapy with autologous stem cell rescue following prior induction therapy [1] 3. Treatment for multiple myeloma patients who have received at least one prior therapy and whose disease has progressed [1] 4. Treatment of adult patients with previously untreated mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]